Ultromics, a leader in AI-driven cardiology solutions, has raised $55 million in Series C financing. This funding round was co-led by L&G, Allegis Capital, and Lightrock, with additional support from organizations like Oxford Science Enterprises and UCHICAGO Medicine’s UCM Ventures.
The company utilizes years of clinical research and extensive echocardiogram data to provide the first FDA-cleared and Medicare-reimbursed AI technology for detecting heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis—two complex forms of heart failure. Ultromics aims to make AI-enhanced diagnostics a standard part of cardiac evaluations as it expands its services to at-risk hospitals and echo labs across the U.S.
Heart failure is a growing concern, with significant healthcare costs—over $30 billion annually in the U.S.—and many patients going undiagnosed. Clinicians often rely on subjective echocardiogram interpretations, which can lead to missed diagnoses. Ultromics addresses this issue using AI to extract hidden disease signals from standard scans, facilitating earlier and more accurate detection without disrupting clinical workflows. Its FDA-cleared EchoGo platform generates real-time probability scores and is fully reimbursed under Medicare, allowing for broad adoption in hospitals and clinics.
To date, Ultromics has analyzed over 430,000 echocardiograms, improving HFpEF detection rates by 73.6% compared to standard risk scores. The company has also validated a model for cardiac amyloidosis that outperformed existing clinical scores.
With partnerships among major institutions like the Mayo Clinic and Northwestern, Ultromics is building regional networks that enhance clinical and commercial success. The company is rapidly expanding its platform, having received FDA Breakthrough Device clearance for EchoGo Amyloidosis and launching EchoGo Score, enhancing HFpEF detection. These advancements are supported by Medicare reimbursement, paving the way for broader adoption across U.S. hospitals.
KEY QUOTES:
“The reality is, hospitals already have the data, they just haven’t had the tools to extract the more subtle diagnostic signals from it. By analyzing routine echocardiograms with AI, we’re helping clinicians identify high-risk patients earlier, enabling intervention before disease progresses. We’ve spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the U.S. at a moment when health systems are actively looking to combat the growing heart failure crisis.”
Ross Upton, PhD, CEO and Founder, Ultromics
“Ultromics has established itself as an early-mover in the large and underserved cardiovascular disease market, having developed one of the first commercially available AI-powered diagnostic echocardiogram technologies. This successful Series C round is a testament to the massive opportunity for cutting-edge technology to transform how clinicians can detect and treat serious cardiovascular diseases that impact millions of people every year.”
Alastair Stewart, Head of Investments, Venture Capital, at L&G
“Heart failure and cardiac amyloidosis impact millions of lives and strain healthcare systems, despite new approaches that have the potential to significantly improve patient outcomes. There is a critical need for scalable solutions that enable earlier, more accurate diagnosis and elevate the standard of care. Ultromics’ AI-driven technology is already making a real-world impact, improving diagnostic accuracy, supporting clinical decisions, and expanding access to specialist care. The Lightrock team is delighted to support Ultromics’ mission and growing impact.”
Umur Hursever, Partner at Lightrock
“There’s a long-standing blind spot in cardiology where millions of patients with treatable heart failure are missed because their symptoms are subtle and echo images are hard to interpret. What’s exciting about Ultromics is how they’re closing that gap. Their platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. When paired with the latest treatment advances, it’s a diagnostic win that will help save lives.”
Victor Westerlind, Managing Director at Allegis Capital
